On October 16, 2012, Exact Sciences Corporation (the "Company") released new study data for its colorectal cancer screening test at the International Conference on Frontiers in Cancer Prevention Research, a meeting of the American Association for Cancer Research. The primary purpose of the study was to establish the analytical performance of the test methodology in advance of completion of the Company's pivotal clinical trial for the test (known as the DeeP-C trial). The study demonstrated 98% sensitivity for cancer. It also demonstrated promising results for detecting the pre-cancers most likely to develop into colon cancer, with 83% sensitivity for high grade dysplasia and 57% for pre-cancer = 1 cm. All sensitivities were reported at a specificity of 90%.
The study specimens were collected at 36 study centers either before colonoscopy bowel preparation in screening and surveillance subjects, or at least seven days post-colonoscopy from subjects recruited with colorectal cancer or pre-cancers. A total of 1003 patient samples were analyzed in the study."
Absolutely, don't let members of the blind stupid luck club trick you into paying a 2000% premium for the very same shares they bought at .50c or lower. They prey upon the stupid and the ill informed. Be Careful.